Patents by Inventor Edwin Walsh
Edwin Walsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240144396Abstract: Methods, systems, and computer storage media for providing a concentrate grade recommendation using a concentrate grade optimization engine in a material processing engine of a material processing system. The concentrate grade recommendation refers to a quantified value for concentrate grade that corresponds to an economic value for ore of a mining process. In operation, input data comprising material processing planning data and economic data associated with a recovery process are accessed. The input data is analyzed using a grade recovery relationship machine learning model. The grade recovery relationship machine learning model is trained on historical material processing data features associated with concentrate grade and recovery of the material recovery process. The historical data includes data on produced concentrate (e.g., achieved grades and corresponding recovery). Based on analyzing the input data, a concentrate grade that corresponds to an economic value is generated.Type: ApplicationFiled: October 31, 2022Publication date: May 2, 2024Inventors: Rohin Wood, Ric Zong-Yang Porteous, Artem Vladimirov, Malcolm James Walsh, Julian Edwin Lovett Cooper
-
Patent number: 11400052Abstract: The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: November 19, 2019Date of Patent: August 2, 2022Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Edwin Walsh, Clark Patrick Allphin
-
Publication number: 20220160640Abstract: The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: February 11, 2022Publication date: May 26, 2022Inventors: Edwin WALSH, Clark Patrick ALLPHIN
-
Publication number: 20200330393Abstract: The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: November 19, 2019Publication date: October 22, 2020Inventors: Edwin WALSH, Clark Patrick ALLPHIN
-
Publication number: 20110052684Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.Type: ApplicationFiled: January 28, 2009Publication date: March 3, 2011Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Edwin Walsh, Graham Jackson, Werner Oberegger, Xiaopin Jin
-
Publication number: 20090246276Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.Type: ApplicationFiled: January 27, 2009Publication date: October 1, 2009Inventors: Graham Jackson, Edwin Walsh, Werner Oberegger, Xiaopin Jin
-
Publication number: 20080138404Abstract: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.Type: ApplicationFiled: November 27, 2007Publication date: June 12, 2008Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Edwin WALSH, Ann Marie YOUNG, Graham JACKSON
-
Patent number: 6031749Abstract: A switch-mode power converter uses a digital signal processor (DSP) to control operation of power semiconductors through gate drive amplifiers, further using the DSP's internal analog-to-digital converters to measure necessary currents, voltages and timings within the main power circuit. Using values captured by the A-to-D converters, software controlling the DSP manipulates duty cycle and timing parameters of the main semiconductor switches to provide at least three different modes of operation for serving a wide range of lighting loads. This power system reduces the size, cost, and weight, of circuitry needed to operate stage lighting equipment. The DSP's microprocessor eliminates most of the complex and dedicated analog circuitry commonly used for electronic power conversion, and a common power circuit topology provides an identical hardware platform for each luminaire circuit. Overall reliability is enhanced because of the reduction in circuit complexity.Type: GrantFiled: March 31, 1999Date of Patent: February 29, 2000Assignee: Vari-Lite, Inc.Inventors: John Henry Covington, Thomas Edwin Walsh, John Mark Newell